Skip to main content

Advertisement

Log in

Phase II trial of titanocene dichloride in advanced renal-cell carcinoma

Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Titanocene dichloride was capable of inhibiting the growth of different types of human tumors in vitro. A total of 14 patients with metastatic renal-cell carcinoma (RCC) received 270 mg/m2 titanocene dichloride every 3 weeks for 6 weeks. Although the toxicities and side effects encountered were mild to moderate, no partial or complete response was detectable. In conclusion, titanocene dichloride has no advantage in the therapy of RCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

Authors

Additional information

Received: 18 February 1998 / Accepted: 23 April 1998

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lümmen, G., Sperling, H., Luboldt, H. et al. Phase II trial of titanocene dichloride in advanced renal-cell carcinoma. Cancer Chemother Pharmacol 42, 415–417 (1998). https://doi.org/10.1007/s002800050838

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002800050838

Navigation